

A comparison of genotype and markers of disease severity of chronic hepatitis C in patients with and without end-stage renal disease

Hassan M R, Mustapha N R N, Zawawi F M, Earnest B S P, Voralu K, Pani S P

Internal Medicine
and Gastroenterology,
Hospital Sultanah
Bahiyah,
KM6,
Jalan Langgar,
Alor Star 05460,
Malaysia

Hassan MR, LRCP&S,
MRCP, MMed
Head

Mustapha NRN,
BAO, MMed
Consultant Pathologist

Zawawi FM, BAO,
LRCP&SI, MMed
Physician and
Gastroenterologist

School of Medicine,
AIMST University,
Jalan Bedong
Smeling,
Bedong 08100,
Malaysia

Earnest BSP,
MBBS, MD
Associate Professor

Clinical Research
Group,
Drexel University
College of Medicine,
3 Parkway Building,
10th floor Suite 1000,
1601 Cherry Street,
Philadelphia,
PA 19102,
USA

Voralu K, MSc
Clinical Research
Coordinator and
Biostatistician

Clinical Microbiology
and Epidemiology,
Faculty of Medicine,
Alliance College of
Medical Sciences,
Waziria Medical
Square,
Kepala Batas 13200,
Malaysia

Pani SP, MD, PhD
Head

Correspondence to:
Dato' Dr Muhammad
Radzi bin Abu Hassan
Tel: (60) 194151565
Fax: (60) 4740 7373
Email: radzi@crc.
gov.my

ABSTRACT

Introduction: This study was conducted to compare the genotype and markers of disease severity of chronic hepatitis C (CHC), namely viral load, alanine transaminase (ALT) levels and histopathological findings on liver biopsy, in patients with and without end-stage renal disease (ESRD).

Methods: This was a cross-sectional retrospective comparative study that included ESRD patients on haemodialysis and non-ESRD patients with CHC who underwent liver biopsy between January 2004 and December 2006. Blood tests for viral load (VL) (hepatitis C virus, ribonucleic acid, polymerase chain reaction), genotyping and ALT were administered. VL was grouped into low (less than $5 \log_{10}$) and high (more than or equal to $5 \log_{10}$) VL, genotype into G1 and 2, 3, 4, and ALT into normal and elevated ALT. Necroinflammatory activity was grouped into mild (G0–6) and moderate/severe (G7–18) activity, and fibrosis into mild (S0–2) and moderate/severe (S3–6) fibrosis. These variables were compared between the two groups.

Results: Genotype 1 was significantly higher in ESRD patients than in non-ESRD patients, in whom genotypes 2, 3 and 4 were higher. Although the proportion of patients with high VL was greater and the duration of CHC was longer in the ESRD group, the ALT levels were lower and the histopathological grading of necroinflammatory activity and stages of fibrosis were less severe in ESRD compared to non-ESRD patients.

Conclusion: The lower levels of ALT observed in CHC patients with ESRD translate to histopathological benefits.

Keywords: dialysis, end-stage renal disease, genotype, hepatitis C, liver fibrosis

Singapore Med J 2011; 52(2): 86-89

INTRODUCTION

Patients on haemodialysis are at a high risk of acquiring chronic hepatitis C (CHC). The incidence of seroconversion is dependent on many factors, including failure in patient isolation (by dedicated equipment, personnel and days for hepatitis C virus [HCV]-positive patients), a break in the use of cross infection prevention measures (such as the use of disposable gloves), the duration of haemodialysis and the number of blood transfusions.⁽¹⁾ The use of dedicated equipment, personnel and days for HCV-positive patients and the retraining of dialysis personnel in the use of cross-infection prevention measures have been shown to reduce the incidence of transmission.⁽²⁾ Furthermore, the growing use of erythropoietin has significantly reduced the requirement for blood transfusions. Still, iatrogenic transmission of HPV among haemodialysis patients remains a challenge worldwide. The risk of death, morbidity, genotyping and the cost of dialysis treatment of CHC patients are much higher than those of non-CHC patients.⁽³⁻⁵⁾

Although iatrogenic factors for transmission have been recorded in many studies, few studies have reported viral and patient factors (such as viral genotype, viral titre, liver enzyme and histological changes) in these patients compared to CHC patients with normal renal function. Earlier studies have reported a higher incidence of genotype 1 among patients with end-stage renal disease (ESRD).⁽³⁾ In this study, we compared the genotype, viral load, alanine transaminase (ALT) and liver histology (necroinflammatory activity and fibrosis) of ESRD with non-ESRD patients with CHC.

METHODS

This was a cross-sectional, retrospective comparative study conducted at the Hospital Sultanah Bahiyah, Alor

Table I. Baseline characteristics of ESRD and non-ESRD patients.

| Variable | No. (%) | | p-value (χ^2) |
|-------------------------|------------------|----------------------|----------------------|
| | ESRD (n = 28) | Non-ESRD (n = 50) | |
| Mean age (yrs) | 44.89 | 40.80 | 0.160* |
| Mean CHC duration (yrs) | 4.56 | 2.25 | 0.000* |
| Gender | | | 0.0809 |
| Female | 16 (57.14) | 17 (34.00) | |
| Male | 12 (42.86) | 33 (66.00) | |
| Race | | | 0.9405 |
| Malay | 18 (64.29) | 32 (64.00) | |
| Chinese | 7 (25.00) | 15 (30.00) | |
| Indian and others | 3 (10.71) | 3 (6.00) | |

* Independent t-test

ESRD: end-stage renal disease; CHC: chronic hepatitis C

Star, Kedah, Malaysia. The inclusion criteria were ESRD and non-ESRD patients on dialysis with CHC, who underwent ultrasonography-guided liver biopsy from January 2004 to December 2006. HCV seropositivity was identified using enzyme-linked immunosorbent assay, which was conducted periodically for ESRD patients on follow-up as part of the unit protocol and for non-ESRD patients attending the hospital. All patients who did not undergo a blood test for viral load (VL) (HCV, ribonucleic acid, polymerase chain reaction, iu/mL), genotyping, ALT (mmol/L) and liver biopsy during that period were excluded from the study. The patients were grouped into CHC patients with ESRD (n = 28) and CHC patients without ESRD (n = 50). In each group, VL was categorised into low (LVL < 5 log₁₀) and high (HVL ≥ 5 log₁₀), genotype into G1 and 2, 3, 4, and ALT into normal and elevated. Liver histology was scored using the Ishak scoring system. Necroinflammatory activity was grouped into mild (G0–6) and moderate/severe (G7–18) activity, and fibrosis was categorised into mild (S0–2) and moderate/severe (S3–6) fibrosis.

Data entry and analysis was performed with EpiInfo version 3.4.1 (Centers for Disease Control and Prevention, Atlanta, GA, USA). The mean and standard deviation were obtained for all numerical variables, and the numbers and percentages for all categorical variables. Statistically significant differences between categorical variables were determined by the chi-square test. Chi-square values (χ^2) and p-values were obtained.

RESULTS

A total of 78 patients who were HCV-seropositive underwent liver biopsy, and their ALT and VL levels were measured. The baseline characteristics of the study population are presented in Table I. The duration of CHC




Fig. 1 Bar chart shows the distribution of hepatitis C virus genotypes among end-stage renal disease (ESRD) and non-ESRD patients.

was substantially longer in ESRD patients than in non-ESRD patients. The proportion of non-ESRD patients with CHC was equal across the races, and much higher among male patients. The proportion of patients with LVL was significantly higher in patients without ESRD. Genotype 1 was significantly higher in ESRD patients than in non-ESRD patients, in whom G2, 3 and 4 were higher (Fig. 1). ALT levels were lower in ESRD patients compared to non-ESRD patients. The proportions of patients with ALT > 1 upper limit of normal (ULN) and ALT > 2 ULN were higher in the non-ESRD group (Fig. 2). Histological grading of necroinflammatory activity and the stage of fibrosis were less severe in ESRD patients compared to non-ESRD patients (Table II). The proportions of patients with moderate/severe grading of necroinflammatory activity and moderate/severe stages of fibrosis were significantly lower in the ESRD group compared to the non-ESRD group.

DISCUSSION

In 1989, Choo et al identified the HCV genome and later proved that it was the major cause of non-A, non-B hepatitis.^(6,7) Aach et al and Alter et al have established that most post-transfusion non-A, non-B hepatitis cases are caused by hepatitis C.^(8,9) Dentico et al have described HCV in haemodialysis patients.⁽¹⁰⁾ Since then, others have reported HCV transmission that is unrelated to blood transfusion in dialysis patients.⁽¹¹⁾ Other researchers have subsequently identified six major serotypes of hepatitis C.⁽¹²⁾ Genotyping of the HCV strains has shown a high prevalence of genotypes 1, 3 and 6 in Southeast Asia and has repeatedly revealed the high prevalence of genotype 1 in haemodialysis units.^(3,13-16) Likewise, our findings show that genotype 1 was the most common HCV genotype in our unit. The higher VLs associated with genotype 1 may be responsible for the higher prevalence of this genotype among haemodialysis patients. Many




Fig. 2 Bar chart shows the alanine transaminase (ALT) levels of end-stage renal disease (ESRD) and non-ESRD patients. ULN: upper limit of normal

studies have indicated that genotype 1 HCV progresses more often to cirrhosis than other genotypes, and an equally large number of similar studies have indicated that cirrhosis is not more common in genotype 1 than in other genotypes. However, genotype 1 does predispose patients to the development of hepatocellular carcinoma and poor response to interferon therapy.⁽¹⁷⁾ The extent to which these findings could be extrapolated to patients with ESRD is yet to be established. The absence of genotype 6 in the current study may be attributable to the small sample size obtained from only one hospital.

Interest in the histopathology of non-A, non-B hepatitis in ESRD patients on dialysis antedates even the identification of the virus or the recognition of it being the cause of hepatitis in dialysis patients.^(18,19) Studies have identified steatosis, various stages of the inflammatory process from nonspecific hepatitis to chronic active hepatitis, cirrhosis and haemosiderosis.⁽²⁰⁾ Previous studies have established that dialysis patients with a high grade of portal necroinflammatory activity had significantly higher aspartate transaminase and ALT levels.⁽²¹⁾ ALT levels were previously found to be lower in CHC patients with ESRD than in patients without ESRD.⁽²²⁾ Our findings are similar to those of previous studies. This has invariably been ascribed to impaired immune response among ESRD patients on dialysis. The extent to which this lowered biochemical marker of hepatic necroinflammatory activity translates to histopathological benefit is not known.

Many previous studies have attempted to compare liver biopsy findings among CHC patients on dialysis with those of CHC patients without ESRD.^(23,24) These studies have also found that necroinflammatory activity and fibrosis were much lower in ESRD patients with CHC than in CHC patients without ESRD. A study by Akpolat et al, which compared nine CHC patients with ESRD and

Table II. Study characteristics of patients with ESRD and non-ESRD.

| Variable | No. (%) [¶] | | p-value |
|--------------------------------------|----------------------|-----------------------|---------------------|
| | ESRD* [‡] | Non-ESRD [‡] | |
| Genotype | | | 0.0002 ^a |
| Geno 1 | 22 (81.5) | 13 (32.5) | |
| Geno 2/3/4 | 5 (18.5) | 27 (67.5) | |
| Grade of necro-inflammatory activity | | | 0.0017 ^b |
| Mild (0–6) | 26 (92.9) | 30 (60.0) | |
| Moderate to severe (7–18) | 2 (7.1) | 20 (40.0) | |
| Stage of fibrosis | | | 0.0128 ^b |
| Mild (0–2) | 24 (85.7) | 29 (58.0) | |
| Moderate to severe (3–6) | 4 (14.3) | 21 (42.0) | |
| Alanine transaminase | | | 0.0003 ^b |
| ≤ 2 ULN | 26 (92.9) | 25 (52.1) | |
| > 2 ULN | 2 (7.1) | 23 (47.9) | |
| Alanine transaminase | | | 0.0023 ^a |
| ≤ 1 ULN | 17 (60.7) | 11 (22.9) | |
| > 1 ULN | 11 (39.3) | 37 (77.1) | |
| Viral load | | | 0.0571 ^a |
| < 5 log ₁₀ | 5 (18.5) | 18 (43.9) | |
| > 5 log ₁₀ | 22 (81.5) | 23 (56.1) | |
| Viral load | | | 0.5582 ^b |
| > 3–4 log ₁₀ | 2 (7.4) | 1 (2.4) | |
| > 4–7 log ₁₀ | 25 (92.6) | 40 (97.6) | |

* Of the 28 ESRD cases, 1 sample could not be tested for Geno class and 1 for viral load, as the samples were inadequate or unsuitable.

† Of the 50 non-ESRD cases, 10 samples could not be tested for Geno class, 2 for ALT and 9 for viral load, as the samples were inadequate or unsuitable.

¶ Percentages are calculated based on the total number of patients tested for each variable.

^a chi-square test ^b Fisher's exact test

ESRD: end-stage renal disease; ULN: upper limit of normal

37 patients without ESRD, showed that haemodialysis patients may have less active and progressive CHC than patients with normal renal function.⁽²³⁾ As the number of patients studied was small, it was suggested that further studies be conducted.⁽²³⁾ Luzar et al compared 13 CHC patients with ESRD and 154 patients without ESRD,⁽²⁴⁾ and observed that non-uremic patients had more hepatic inflammatory activity and progression of fibrosis compared to uremic patients who were treated with haemodialysis.

The current study compared 28 CHC patients with ESRD and 50 patients without ESRD. The predominant HCV genotype in ESRD patients was type 1. Significant differences were observed between HCV-infected uremic and non-uremic patients in terms of their genotype, ALT levels, extent of necroinflammatory activity and fibrosis, revealing less severe disease activity in the ESRD group. Some studies have compared liver biopsy findings in

CHC patients on dialysis with those of CHC patients who had undergone renal transplant.^(25,26) There was a larger proportion of renal transplant cases with higher degrees of hepatic fibrosis and liver cell necrosis than ESRD patients on dialysis, suggesting that renal transplantation may lead to more aggressive liver disease. These findings also correlate well with our conclusion that dialysis influences the natural history of CHC in ESRD patients and makes it less aggressive.

One possible explanation for the observed phenomenon is the elevation of the hepatocyte growth factor during dialysis in patients with ESRD.⁽²⁷⁾ However, we cannot rule out the possibility that asymptomatic CHC in ESRD patients might have been detected earlier due to better screening, as the two groups were not precisely matched. One group consisted of ESRD patients who were screened periodically for HCV and liver disease, while the other consisted of patients with symptomatic liver disease. The fact that the duration of disease in ESRD patients was twice as long as in those without ESRD may at least partially offset this. Although the difference in the duration of disease was highly significant statistically, this should be interpreted with caution, considering the slow progression of CHC, often over the course of decades. Moreover, since our sample size was small, these findings need to be confirmed with larger studies. In conclusion, this study has shown that necroinflammatory activity and fibrosis are much less prevalent among ESRD patients with CHC than among CHC patients without ESRD despite the longer duration of illness and a higher VL in the ESRD group.

ACKNOWLEDGEMENT

The authors acknowledge the technical assistance rendered by the Malaysian Liver Foundation, Petaling Jaya, Selangor Darul Ehsan, Malaysia.

REFERENCES

- Santos MA, Souto FJ. Infection by the hepatitis C virus in chronic renal failure patients undergoing hemodialysis in Mato Grosso state, central Brazil: a cohort study. *BMC Public Health* 2007; 7:32.
- Engel M, Malta FM, Gomes MM, et al. Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil. *BMC Public Health* 2007; 7:50.
- Soetjijto, Handajani R, Lusida MI, et al. Differential prevalence of hepatitis C virus subtypes in healthy blood donors, patients on maintenance hemodialysis, and patients with hepatocellular carcinoma in Surabaya, Indonesia. *J Clin Microbiol* 1996; 34:2875-80.
- Wang SM, Liu JH, Chou CY, et al. Mortality in hepatitis C-positive patients treated with peritoneal dialysis. *Perit Dial Int* 2008; 28:183-7.
- Vanholder R, Van Biesen W. Incidence of infectious morbidity and mortality in dialysis patients. *Blood Purif* 2002; 20:477-80.
- Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 1989; 244:359-62.
- Choo QL, Weiner AJ, Overby LR, et al. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. *Br Med Bull* 1990; 46:423-41.
- Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. *N Eng J Med* 1991; 325:1325-9.
- Alter HJ, Purcell RH, Shih JW, et al. Detection of antibodies to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. *N Eng J Med* 1989; 321:1494-500.
- Dentico P, Volpe A, Buongiorno R, et al. Hepatitis C virus in hemodialysis patients. *Nephron* 1992; 61:307-8.
- Irie Y, Hayashi H, Yokozeki K, Kashima T, Okuda K. Hepatitis C infection unrelated to blood transfusion in hemodialysis patients. *J Hepatol* 1994; 20:557-9.
- Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into 6 major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. *J Gen Virol* 1993; 74:2391-9.
- Schneeberger PM, Keur I, van der Vliet W, et al. Hepatitis C virus infection in dialysis centers in The Netherlands: a national survey by serological and molecular methods. *J Clin Microbiol* 1998; 36:1711-5.
- Hinrichsen H, Leimenstoll G, Stegen G, et al. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. *Gut* 2002; 51:429-33.
- de Paula Farah K, Carmo RA, de Figueiredo Antunes CM, et al. Hepatitis C, HCV genotypes and hepatic siderosis in patients with chronic renal failure on haemodialysis in Brazil. *Nephrol Dial Transplant* 2007; 22:2027-31.
- Pybus OG, Barnes E, Taggart R, et al. Genetic history of hepatitis C virus in East Asia. *J Virol* 2009; 83:1071-82.
- Simmonds P. Clinical relevance of hepatitis C virus genotypes. *Gut* 1997; 40:291-3.
- Parfrey PS, Farge D, Forbes RD, et al. Chronic hepatitis in end-stage renal disease: comparison of HBsAg-negative and HBsAg-positive patients. *Kidney Int* 1985; 28:959-67.
- Gilli P, Cavazzini L, Stabellini N, et al. Histological features of non-A, non-B hepatitis in hemodialysis patients. *Nephron* 1992; 61:296-7.
- al-Wakeel J, Malik GH, al-Mohaya S, et al. Liver disease in dialysis patients with antibodies to hepatitis C virus. *Nephrol Dial Transplant* 1996; 11:2265-8.
- Sezer S, Ozdemir BH, Arat Z, et al. Spectrum of liver damage and correlation with clinical and laboratory parameters in HCV infected hemodialysis patients. *Ren Fail* 2001; 23:807-18.
- Azevedo HA, Villela-Nogueira CA, Perez RM, et al. Similar HCV viral load levels and genotype distribution among end-stage renal disease patients on hemodialysis and HCV-infected patients with normal renal function. *J Nephrol* 2007; 20:609-16.
- Akpolat I, Ozyilkan E, Karagöz F, Akpolat T, Kandemir B. Hepatitis C in haemodialysis and nonuraemic patients: a histopathological study. *Int Urol Nephrol* 1998; 30:349-55.
- Luzar B, Ferlan-Marolt V, Brinovec V, et al. Does end-stage kidney failure influence hepatitis C progression in hemodialysis patients? *Hepatology* 2003; 50:157-60.
- Perez RM, Ferreira AS, Medina-Pestana JO, et al. Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease? *J Clin Gastroenterol* 2006; 40:444-8.
- Glicklich D, Thung SN, Kapoian T, Tellis V, Reinus JF. Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients. *Am J Gastroenterol* 1999; 94:159-63.
- Rampino T, Libetta C, Mazzone A, et al. Hepatocyte growth factor protects the liver against hepatitis C virus in patients on regular hemodialysis. *J Chemother* 1998; 10:164-6.